Galectin Therapeutics (NASDAQ: GALT) announces that preclinical research from a study led by Stefanie Linch, Ph.D. in the laboratory of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Research Underlying Galectin's Development of GR-MD-02 in Cancer Presented at the Society for Immunotherapy of Cancer Annual MeetingNovember 11, 2015 8:01 AM Galectin Therapeutics (GALT) Misses Q3 EPS by 6cNovember 9, 2015 8:04 AM